Aubree Gordon1, Lionel Gresh2, Sergio Ojeda2, Gerardo Chowell3, Karla Gonzalez2,4, Nery Sanchez2, Saira Saborio2,4, Juan Carlos Mercado2,4, Guillermina Kuan2,5, Angel Balmaseda2,4, Eva Harris1,6. 1. Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor. 2. Sustainable Sciences Institute, Managua, Nicaragua. 3. Georgia State University, Atlanta. 4. Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia. 5. Centro de Salud Sócrates Flores Vivas, Ministerio de Salud, Managua, Nicaragua. 6. Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley.
Abstract
Background: Chikungunya, an arboviral disease, caused massive epidemics in Central and South America in 2014-2016. In a prospective pediatric cohort study, we examined the introduction of chikungunya in a naive population and investigated transmission and clinical characteristics. Methods: Children presenting to the study health center with a chikungunya-like illness or undifferentiated fever were tested for chikungunya virus (CHIKV) infection by reverse transcriptase-polymerase chain reaction (RT-PCR) and serological assays. Inapparent CHIKV infections in the intervening year were determined by seroconversion in healthy blood samples collected annually. Results: A total of 4353 children participated in the cohort study from March 2014 to February 2016 during the 2 epidemic waves of chikungunya. A total of 539 cases of chikungunya were documented, for an incidence rate of 80.2 cases per 1000 person-years (95% confidence interval [CI]: 73.7, 87.2); and a total of 893 CHIKV infections were documented, for an incidence rate of 137.1 infections per 1000 person-years (95% CI: 128.4, 146.4). The seroprevalence of anti-CHIKV antibodies increased linearly with age, with seroprevalence of >45% in 14-year-old children at the end of Epidemic 2. Symptom presentation varied between the epidemics, with Epidemic 2 exhibiting both a higher symptomatic-to-inapparent ratio (1:1.20 in Epidemic 1 vs. 1:0.65 in Epidemic 2) and more severe clinical presentation among cases. The mean reproduction number was also greater in Epidemic 2 than in Epidemic 1. Conclusions: The intensity of transmission and severity of clinical presentation varied between the 2 epidemics, with higher transmission intensity associated with greater disease severity.
Background: Chikungunya, an arboviral disease, caused massive epidemics in Central and South America in 2014-2016. In a prospective pediatric cohort study, we examined the introduction of chikungunya in a naive population and investigated transmission and clinical characteristics. Methods:Children presenting to the study health center with a chikungunya-like illness or undifferentiated fever were tested for chikungunya virus (CHIKV) infection by reverse transcriptase-polymerase chain reaction (RT-PCR) and serological assays. Inapparent CHIKV infections in the intervening year were determined by seroconversion in healthy blood samples collected annually. Results: A total of 4353 children participated in the cohort study from March 2014 to February 2016 during the 2 epidemic waves of chikungunya. A total of 539 cases of chikungunya were documented, for an incidence rate of 80.2 cases per 1000 person-years (95% confidence interval [CI]: 73.7, 87.2); and a total of 893 CHIKV infections were documented, for an incidence rate of 137.1 infections per 1000 person-years (95% CI: 128.4, 146.4). The seroprevalence of anti-CHIKV antibodies increased linearly with age, with seroprevalence of >45% in 14-year-old children at the end of Epidemic 2. Symptom presentation varied between the epidemics, with Epidemic 2 exhibiting both a higher symptomatic-to-inapparent ratio (1:1.20 in Epidemic 1 vs. 1:0.65 in Epidemic 2) and more severe clinical presentation among cases. The mean reproduction number was also greater in Epidemic 2 than in Epidemic 1. Conclusions: The intensity of transmission and severity of clinical presentation varied between the 2 epidemics, with higher transmission intensity associated with greater disease severity.
Authors: In-Kyu Yoon; Anon Srikiatkhachorn; Laura Hermann; Darunee Buddhari; Thomas W Scott; Richard G Jarman; Jared Aldstadt; Ananda Nisalak; Suwich Thammapalo; Piraya Bhoomiboonchoo; Mammen P Mammen; Sharone Green; Robert V Gibbons; Timothy P Endy; Alan L Rothman Journal: Am J Trop Med Hyg Date: 2013-10-14 Impact factor: 2.345
Authors: Nguyen Thi Kim Tien; Christine Luxemburger; Nguyen Trong Toan; Laurence Pollissard-Gadroy; Vu Thi Que Huong; Pham Van Be; Nguyen Ngoc Rang; Tram-Anh Wartel; Jean Lang Journal: Trans R Soc Trop Med Hyg Date: 2010-07-13 Impact factor: 2.184
Authors: Kibet Sergon; Ali Ahmed Yahaya; Jennifer Brown; Said A Bedja; Mohammed Mlindasse; Naphtali Agata; Yokouide Allaranger; Mamadou D Ball; Ann M Powers; Victor Ofula; Clayton Onyango; Limbaso S Konongoi; Rosemary Sang; M Kariuki Njenga; Robert F Breiman Journal: Am J Trop Med Hyg Date: 2007-06 Impact factor: 2.345
Authors: Kibet Sergon; Charles Njuguna; Rosalia Kalani; Victor Ofula; Clayton Onyango; Limbaso S Konongoi; Sheryl Bedno; Heather Burke; Athman M Dumilla; Joseph Konde; M Kariuki Njenga; Rosemary Sang; Robert F Breiman Journal: Am J Trop Med Hyg Date: 2008-02 Impact factor: 2.345
Authors: Thomas S Churcher; Robert E Sinden; Nick J Edwards; Ian D Poulton; Thomas W Rampling; Patrick M Brock; Jamie T Griffin; Leanna M Upton; Sara E Zakutansky; Katarzyna A Sala; Fiona Angrisano; Adrian V S Hill; Andrew M Blagborough Journal: PLoS Pathog Date: 2017-01-12 Impact factor: 6.823
Authors: Patrick Gérardin; Georges Barau; Alain Michault; Marc Bintner; Hanitra Randrianaivo; Ghassan Choker; Yann Lenglet; Yasmina Touret; Anne Bouveret; Philippe Grivard; Karin Le Roux; Séverine Blanc; Isabelle Schuffenecker; Thérèse Couderc; Fernando Arenzana-Seisdedos; Marc Lecuit; Pierre-Yves Robillard Journal: PLoS Med Date: 2008-03-18 Impact factor: 11.069
Authors: Freddy Perez; Anthony Llau; Gamaliel Gutierrez; Haroldo Bezerra; Giovanini Coelho; Steven Ault; Sulamita Brandao Barbiratto; Marcelo Carballo de Resende; Lizbeth Cerezo; Giovanni Luz Kleber; Oscar Pacheco; Octavio Lenin Perez; Victor Picos; Diana P Rojas; Joao Bosco Siqueira; Marco Fidel Suarez; Eva Harris; Luis Gerardo Castellanos; Carlos Espinal; Jose Luis San Martin Journal: Trop Med Int Health Date: 2019-01-28 Impact factor: 2.622
Authors: Leah C Katzelnick; Rotem Ben-Shachar; Juan Carlos Mercado; Isabel Rodriguez-Barraquer; Douglas Elizondo; Sonia Arguello; Andrea Nuñez; Sergio Ojeda; Nery Sanchez; Brenda Lopez Mercado; Lionel Gresh; Raquel Burger-Calderon; Guillermina Kuan; Aubree Gordon; Angel Balmaseda; Eva Harris Journal: Proc Natl Acad Sci U S A Date: 2018-09-28 Impact factor: 11.205
Authors: Guilherme S Ribeiro; Gabriel L Hamer; Mawlouth Diallo; Uriel Kitron; Albert I Ko; Scott C Weaver Journal: Curr Opin Virol Date: 2020-03-17 Impact factor: 7.090
Authors: Marcos A Espinal; Jon K Andrus; Barbara Jauregui; Stephen Hull Waterman; David Michael Morens; Jose Ignacio Santos; Olaf Horstick; Lorraine Ayana Francis; Daniel Olson Journal: Am J Public Health Date: 2019-01-24 Impact factor: 9.308
Authors: Rosângela O Anjos; Vánio André Mugabe; Patrícia S S Moreira; Caroline X Carvalho; Moyra M Portilho; Ricardo Khouri; Gielson A Sacramento; Nivison R R Nery; Mitermayer G Reis; Uriel D Kitron; Albert I Ko; Federico Costa; Guilherme S Ribeiro Journal: Emerg Infect Dis Date: 2020-07 Impact factor: 6.883